Unione Europea - italiano - EMA (European Medicines Agency)

novartis europharm limited - asciminib hydrochloride - leucemia, myelogenous, chronic, bcr-abl positive - agenti antineoplastici - scemblix is indicated for the treatment of adult patients with philadelphia chromosome positive chronic myeloid leukaemia in chronic phase (ph+ cml cp) previously treated with two or more tyrosine kinase inhibitors (see section 5.

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

novartis pharma schweiz ag - asciminibum - compresse rivestite con film - asciminibum 20 mg ut asciminibi hydrochloridum 21.62 mg, lactosum monohydricum 43.11 mg, cellulosum microcristallinum, hydroxypropylcellulosum substitutum humile, carmellosum natricum conexum, poly(alcohol vinylicus), e 171, magnesii stearas, talcum, silica colloidalis anhydrica, lecithinum, e 172 (flavum), e 172 (rubrum), xanthani gummi, pro compresso obducto corresp. natrium max. 0.47 mg. - behandlung von erwachsenen patienten mit philadelphia-chromosom-positiver chronisch-myeloischer leukämie (ph+ cml) in der chronischen phase (cp) - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

novartis pharma schweiz ag - asciminibum - compresse rivestite con film - asciminibum 40 mg ut asciminibi hydrochloridum 43.24 mg, lactosum monohydricum 86.22 mg, cellulosum microcristallinum, hydroxypropylcellulosum substitutum humile, carmellosum natricum conexum, poly(alcohol vinylicus), e 171, magnesii stearas, talcum, silica colloidalis anhydrica, lecithinum, e 172 (rubrum), e 172 (nigrum), xanthani gummi, pro compresso obducto corresp. natrium max. 0.93 mg. - behandlung von erwachsenen patienten mit philadelphia-chromosom-positiver chronisch-myeloischer leukämie (ph+ cml) in der chronischen phase (cp) - synthetika